Onconetix Inc (ONCO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Onconetix Inc (ONCO) has a cash flow conversion efficiency ratio of -0.941x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.18 Million) by net assets ($3.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Onconetix Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Onconetix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See what is Onconetix Inc's book value for net asset value and shareholders' equity analysis.
Onconetix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Onconetix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yolo SA
WAR:YOL
|
0.005x |
|
AOTI Inc
LSE:AOTI
|
-0.037x |
|
OSX Brasil S.A
SA:OSXB3
|
-0.001x |
|
First Tin PLC
LSE:1SN
|
-0.028x |
|
LABOCANNA S.A. ZY-10
F:9Y2
|
-0.043x |
|
Nulegacy Gold Corporation
V:NUG
|
-0.070x |
|
Aurora Solar Technologies Inc
V:ACU
|
0.477x |
|
Dixie Gold Inc
V:DG
|
-0.501x |
Annual Cash Flow Conversion Efficiency for Onconetix Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Onconetix Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Onconetix Inc (ONCO) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $9.61 Million | $-10.50 Million | -1.092x | +88.71% |
| 2023-12-31 | $1.40 Million | $-13.58 Million | -9.670x | -2395.38% |
| 2022-12-31 | $22.39 Million | $-8.68 Million | -0.388x | +72.58% |
| 2021-12-31 | $1.45 Million | $-2.04 Million | -1.413x | -286.65% |
| 2020-12-31 | $4.73 Million | $-1.73 Million | -0.365x | -165.70% |
| 2019-12-31 | $6.00 Million | $-825.13K | -0.138x | -- |
About Onconetix Inc
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other prod… Read more